Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors

Veterinary Immunology and Immunopathology

Volumn 139, Issue 1, 2011, Pages 50-56

  Hezmee, Mohd Noor Mohd ^a   Kyaw Tanner, Myat ^a   Lee, Jia Yu Peppermint ^a   Shiels, Ian A ^a   Rolfe, Barbara ^a   Woodruff, Trent ^a   Mills, Paul C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

C5a receptor; Canine mammary tumor; Complement factor C5a; Polymerase chain reaction (PCR)

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; CARCINOGENESIS; DOG; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATION; MYOEPITHELIOMA; NONHUMAN; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CARCINOMA; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MYOEPITHELIOMA; RECEPTOR, ANAPHYLATOXIN C5A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

CANIS FAMILIARIS;

EID: 78650174354     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2010.08.005     Document Type: Article

References (60)

1. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25:3389-3402.
2. Arumugam T.V., Shiels I.A., Woodruff T.M., Granger D.N., Taylor S.M. The role of the complement system in ischemia-reperfusion injury. Shock 2004, 21:401-409.
3. Chenoweth D.E., Hugli T.E. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:3943-3947.
4. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
5. Coyle Y.M. The effect of environment on breast cancer risk. Breast Cancer Res. Treat. 2004, 84:273-288.
6. DeNardo D.G., Johansson M., Coussens L.M. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008, 27:11-18.
7. de M Souza C.H., Toledo-Piza E., Amorin R., Barboza A., Tobias K.M. Inflammatory mammary carcinoma in 12 dogs; clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can. Vet. J. 2009, 50:506-510.
8. Etschmann B., Wilcken B., Stoevesand K., von der Schulenburg A., Sterner-Kock A. Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. Vet. Pathol. 2006, 43:934-942.
9. Floreani A.A., Gunselman S.J., Heires A.J., Hauke R.J., Jackson J.D. Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma. Cell Cycle 2007, 15:2835-2839.
10. Fukuoka Y., Ember J.A., Yasui A., Hugli T.E. Cloning and characterization of the guinea pig C5a anaphylatoxin receptor: interspecies diversity among the C5a receptors. Int. Immunol. 1998, 10:275-283.
11. Gelderman K.A., Blok V.T., Fleuren G.J., Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Invest. 2002, 82:483-493.
12. Gerard N.P., Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991, 349:614-617.
13. Goldstein I.M., Weissmann G. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J. Immunol. 1974, 113:1583-1588.
14. Haviland D.L., McCoy R.L., Whitehead W.T., Akama H., Molmenti E.P., Brown A., Haviland J.C., Parks W.C., Perlmutter D.H., Wetsel R.A. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. 1995, 154:1861-1869.
15. Hawlisch H., Wills-Karp M., Karp C.L., Kohl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol. Immunol. 2004, 41:123-131.
16. Hellmén, E., 2005. Complex mammary tumours in the female dog: a review. J. Dairy Res. 72 Spec No:90-97.
17. Imai M., Ohta R., Okada N., Tomlinson S. Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma. Int. J. Cancer 2004, 110:875-881.
18. Kim D.Y., Martin C.B., Lee S.N., Martin B.K. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle. Cancer Immunol. Immunother. 2005, 54:1026-1037.
19. Kirschfink M. Targeting complement in therapy. Immunol. Rev. 2001, 180:177-189.
20. Klopfleisch R., Gruber A.D. Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res. Vet. Sci. 2009, 87:91-96.
21. Krishnamoorthy S., Honn K.V. Inflammation and disease progression. Cancer Metastasis Rev. 2006, 25:481-491.
22. Kurimoto Y., de Weck A.L., Dahinden C.A. Interleukin 3-dependent mediator release in basophils triggered by C5a. J. Exp. Med. 1989, 170:467-479.
23. Laudes I.J., Chu J.C., Huber-Lang M., Guo R.F., Riedemann N.C., Sarma J.V., Mahdi F., Murphy H.S., Speyer C., Lu K.T., Lambris J.D., Zetoune F.S., Ward P.A. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 2002, 169:5962-5970.
24. Laudes I.J., Chu J.C., Sikranth S., Huber-Lang M., Guo R.F., Riedemann N., Sarma J.V., Schmaier A.H., Ward P.A. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 2002, 160:1867-1875.
25. Linton S.M., Morgan B.P. Complement activation and inhibition in experimental models of arthritis. Mol. Immunol. 1999, 36:905-914.
26. Liu B., Shi Z.L., Feng J., Tao H.M. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol. Int. 2008, 32:494-501.
27. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
28. Macor P., Tedesco F. Complement as effector system in cancer immunotherapy. Immunol. Lett. 2007, 111:6-13.
29. Marder S.R., Chenoweth D.E., Goldstein I.M., Perez H.D. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J. Immunol. 1985, 134:3325-3331.
30. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9:1225-1235.
31. Misdorp W., Cotchin E., Hampe J.F., Jabara A.G., von Sandersleben J. Canine malignant mammary tumors. I. Sarcomas. Vet. Pathol. 1971, 8:99-117.
32. Misdorp W., Cotchin E., Hampe J.F., Jabara A.G., Von Sandersleben J. Canine malignant mammary tumors. 3. Special types of carcinomas, malignant mixed tumors. Vet. Pathol. 1973, 10:241-256.
33. Mol J.A., Lantinga-van Leeuwen I.S., van Garderen E., Selman P.J., Oosterlaken-Dijksterhuis M.A., Schalken J.A., Rijnberk A. Mammary growth hormone and tumorigenesis-lessons from the dog. Vet. Q. 1999, 21:111-115.
34. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., Lambris J.D. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869-1877.
35. Moulton J. Tumors of the skin and soft tissues. Tumors in Domestic Animals 1990, 23. University of California Press, Berkeley, LA. J. Moulton (Ed.).
36. Nemali S., Siemsen D.W., Nelson L.K., Bunger P.L., Faulkner C.L., Rainard P., Gauss K.A., Jutila M.A., Quinn M.T. Molecular analysis of the bovine anaphylatoxin C5a receptor. J. Leukoc. Biol. 2008, 84:537-549.
37. Niculescu F., Rus H.G., Retegan M., Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 1992, 140:1039-1043.
38. Niehans G.A., Cherwitz D.L., Staley N.A., Knapp D.J., Dalmasso A.P. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 1996, 149:129-142.
39. Onuma H., Masuko-Hongo K., Yuan G., Sakata M., Nakamura H., Kato T., Aoki H., Nishioka K. Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes. Rheumatol. Int. 2002, 22:52-55.
40. Owen L.N. A comparative study of canine and human breast cancer. Invest. Cell Pathol. 1979, 2:257-276.
41. Perez Alenza M.D., Tabanera E., Pena L. Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J. Am. Vet. Med. Assoc. 2001, 219:1110-1114.
42. Perret J.J., Raspe E., Vassart G., Parmentier M. Cloning and functional expression of the canine anaphylatoxin C5a receptor. Evidence for high interspecies variability. Biochem. J. 1992, 288(Pt. 3):911-917.
43. Philip M., Rowley D.A., Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol. 2004, 14:433-439.
44. Qin J., Yuan J., Li L., Liu H., Qin R., Qin W., Chen B., Wang H., Wu K. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomed. Pharmacother. 2009, 63:241-248.
45. Revollo I., Nishiura H., Shibuya Y., Oda Y., Nishino N., Yamamoto T. Agonist and antagonist dual effect of the cross-linked S19 ribosomal protein dimer in the C5a receptor-mediated respiratory burst reaction of phagocytic leukocytes. Inflamm. Res. 2005, 54:82-90.
46. Riedemann N.C., Guo R.F., Sarma V.J., Laudes I.J., Huber-Lang M., Warner R.L., Albrecht E.A., Speyer C.L., Ward P.A. Expression and function of the C5a receptor in rat alveolar epithelial cells. J. Immunol. 2002, 168:1919-1925.
47. Robbins R.A., Russ W.D., Rasmussen J.K., Clayton M.M. Activation of the complement system in the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1987, 135:651-658.
48. Sacks T., Moldow C.F., Craddock P.R., Bowers T.K., Jacob H.S. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J. Clin. Invest. 1978, 61:1161-1167.
49. Schneider R., Dorn C.R., Taylor D.O. Factors influencing canine mammary cancer development and postsurgical survival. J. Natl. Cancer Inst. 1969, 43:1249-1261.
50. Schumacher W.A., Fantone J.C., Kunkel S.E., Webb R.C., Lucchesi B.R. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions 1991, 34:345-349.
51. Sonnenschein E.G., Glickman L.T., Goldschmidt M.H., McKee L.J. Body conformation, diet, and risk of breast cancer in pet dogs: a case-control study. Am. J. Epidemiol. 1991, 133:694-703.
52. Strandberg J.D., Goodman D.G. Animal model of human disease: canine mammary neoplasia. Am. J. Pathol. 1974, 75:225-228.
53. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117:1137-1146.
54. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 2007, 19:209-216.
55. Ward P.A. The dark side of C5a in sepsis. Nat. Rev. Immunol. 2004, 4:133-142.
56. Welch T.R. Complement in glomerulonephritis. Nat. Genet. 2002, 31:333-334.
57. Werfel T., Oppermann M., Schulze M., Krieger G., Weber M., Gotze O. Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992, 79:152-160.
58. Woodruff T.M., Strachan A.J., Sanderson S.D., Monk P.N., Wong A.K., Fairlie D.P., Taylor S.M. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 2001, 25:171-177.
59. Woodruff T., Ager R., Tenner A., Noakes P., Taylor S. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromol. Med. 2010, 12:179-192.
60. Woodruff T.M., Pollitt S., Proctor L.M., Stocks S.Z., Manthey H.D., Williams H.M., Mahadevan I.B., Shiels I.A., Taylor S.M. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 2005, 314:811-817.